Enochian Biosciences Announces Scientific Presentations at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting
LOS ANGELES, April 09, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer,announces that all three submissions to the 23rd Annual Meeting of the ASCGT were accepted for presentation.
- Three of three abstracts were accepted for presentation at the Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT);
- The presentations advance the scientific foundation of Enochian’s broad and deep pipeline for potential cures for HIV and Hepatitis B Virus (HBV) infection
LOS ANGELES, April 09, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that all three submissions to the 23rd Annual Meeting of the ASCGT were accepted for presentation. The Conference will be held virtually May 12-15, 2020.
Dr. Serhat Gumruçku, inventor and co-founder, will have two presentations: Hijacking HBV Pol to Induce Apoptosis Specifically in Infected Hepatocytes In Vivo: A Novel Approach for Potential Treatment or Cure; and Increased Engraftment of Gene Modified HSPCs Overexpressing ALDH1 Using In Vivo Chemoselection. Dr. Ramesh Halder, Senior Staff Scientist, will present: Gene Modified CD34+Cells With Increased ALDH1 Expression Confers In Vitro Protection Against Cyclophosphamide.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” plans,” “expects,” “aims,” “intends” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Enochian undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Contact: [email protected]
